BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 16322312)

  • 1. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma.
    Otto M; Barfield RC; Martin WJ; Iyengar R; Leung W; Leimig T; Chaleff S; Gillies SD; Handgretinger R
    Clin Cancer Res; 2005 Dec; 11(23):8486-91. PubMed ID: 16322312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
    Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
    J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human gammadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation.
    Otto M; Barfield RC; Iyengar R; Gatewood J; Müller I; Holladay MS; Houston J; Leung W; Handgretinger R
    J Immunother; 2005; 28(1):73-8. PubMed ID: 15614047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis.
    Chen Z; Freedman MS
    Clin Immunol; 2008 Aug; 128(2):219-27. PubMed ID: 18501678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells.
    Oberg HH; Peipp M; Kellner C; Sebens S; Krause S; Petrick D; Adam-Klages S; Röcken C; Becker T; Vogel I; Weisner D; Freitag-Wolf S; Gramatzki M; Kabelitz D; Wesch D
    Cancer Res; 2014 Mar; 74(5):1349-60. PubMed ID: 24448235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
    Neal ZC; Yang JC; Rakhmilevich AL; Buhtoiarov IN; Lum HE; Imboden M; Hank JA; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
    Clin Cancer Res; 2004 Jul; 10(14):4839-47. PubMed ID: 15269160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
    Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
    Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model.
    Ren-Heidenreich L; Davol PA; Kouttab NM; Elfenbein GJ; Lum LG
    Cancer; 2004 Mar; 100(5):1095-103. PubMed ID: 14983507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
    Sondel PM; Hank JA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.
    Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K
    J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
    Cheung NK; Modak S
    Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel five-colour flow cytometric assay to determine NK cell cytotoxicity against neuroblastoma and other adherent tumour cells.
    Klöss S; Bochennek K; Huenecke S; Zimmermann SY; Kuçi S; Müller T; Wels WS; Klingebiel T; Esser R; Koehl U
    J Immunol Methods; 2007 Aug; 325(1-2):140-7. PubMed ID: 17663991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
    Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
    Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmodium berghei XAT: contribution of gammadelta T cells to host defense against infection with blood-stage nonlethal malaria parasite.
    Kobayashi F; Niikura M; Waki S; Matsui T; Fujino T; Tsuruhara T; Kamiya S
    Exp Parasitol; 2007 Dec; 117(4):368-75. PubMed ID: 17601562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innate anti-breast cancer immunity of apoptosis-resistant human gammadelta-T cells.
    Guo BL; Liu Z; Aldrich WA; Lopez RD
    Breast Cancer Res Treat; 2005 Sep; 93(2):169-75. PubMed ID: 16187237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
    Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
    Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
    Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
    J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
    Aswald JM; Wang XH; Aswald S; Lutynski A; Minden MD; Messner HA; Keating A
    Cytometry B Clin Cytom; 2006 Nov; 70(6):379-90. PubMed ID: 16977635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. gammadelta T cells: a new frontier for immunotherapy?
    Lamb LS; Lopez RD
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):161-8. PubMed ID: 15744234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.